Subscribe Now »

Special Holiday Deal

Give the Gift of the

Give one person a magazine subscription for $29.95, and get each additional subscription for just $19.95.


Get Well+Being delivered to your inbox every Monday Morning.

Study: Gene Therapy Blocks HIV Infection in Mice
Results show promise of finding an effective vaccine against the human immunodeficiency virus. By Melissa Romero
Comments () | Published December 1, 2011
December 1, 2011 is World AIDS Day.

Scientists have some good news just in time for World AIDS Day. A team at the California Institute of Technology says they’ve developed a new, successful treatment that completely protects mice from HIV infection.

The approach, called Vectored ImmunoProphylaxis (VIP), involves injecting mice with protective antibodies. Usual efforts to prevent HIV infection required the immune system to create antibodies. The VIP process skips that step entirely.

Post-injection, the mice continued to produce high concentrations of antibodies for the rest of their lives. These antibodies effectively prevented any infections from later injections of HIV, including even higher doses of the virus.

While the research is a breakthrough in HIV/AIDS research, it does not mean the VIP approach will work in humans. However, it’s still promising, especially since more than 2 million adults are infected with HIV every year, and 3 percent of Washingtonians are living with HIV/AIDS—the highest rate in the nation.

Watch a video of Caltech researchers talking about their findings.


Subscribe to Washingtonian

Discuss this story

Feel free to leave a comment or ask a question. The Washingtonian reserves the right to remove or edit content once posted.
blog comments powered by Disqus

Posted at 02:11 PM/ET, 12/01/2011 RSS | Print | Permalink | Comments () | Blogs